Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vivozon Pharmaceutical, a South Korean company specializing in the development and distribution of pharmaceutical drugs, is seeking to raise 250 million won ($17.2 million) as it prepares to launch ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say Journavx is an important alternative because the power of opioids helped fuel an ...

Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help ...

Beyond wanting to create more effective drugs, the motivations for constant attempts to produce new, non-opioid painkillers are largely either commercial — because opioid availability is limited ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...

And the big headline here is that it’s not an opioid, and it’s non-addictive. So how does it work? Who should take it? Does it signal a new era for pain medication? Here to help break down this new ...

Advancements have been made in the pain management field that have successfully found FDA approved alternatives to ...